FDA advisers weigh opening the door to seven buzzy peptides
An FDA advisory panel is voting on whether seven peptides can be compounded legally, a move that could widen U.S. access despite safety concerns.
By Sal Moretti · Money Reporter
3 min read
Seven peptides popular in fitness, longevity and med-spa circles are getting a high-stakes review at the Food and Drug Administration this week, with independent advisers set to vote Thursday and Friday on whether they should be reclassified for legal compounding.
The list includes BPC-157, KPV, TB-500, MOTS-C, emideltide, epitalon and Semax. If the FDA allows the reclassification, compounding pharmacies could legally make the products, potentially turning a gray-market wellness trend into a much more accessible U.S. business.
MarketWatch reported that the possible shift could benefit companies tied to compounding pharmacies, including Noom and Hims & Hers Health, as well as dermatology practices, medical spas and clinicians serving consumers interested in recovery, sleep and metabolic health.
Hims told the FDA in public comments that Americans are already using peptide therapies for sleep, recovery and metabolic issues, and said the missing piece is “the structured medical framework” needed to track use, protect patients and improve outcomes.
Why the vote matters
The FDA restricted 14 peptides three years ago because of safety concerns, according to MarketWatch. Since then, some users have continued seeking peptides through products labeled for research use, including ingredients obtained from labs in China, then mixing and injecting them.
Supporters of reclassification argue that bringing the products into a regulated compounding system would add medical oversight. MarketWatch cited a survey of 500 doctors familiar with peptides in which 48% said patients had told them in the past year that they used a peptide not approved by the FDA.
FDA staff have advised against reclassifying the seven peptides. In their report, the agency’s scientists cited limited research, few approvals in other countries and concerns about manufacturing, including how active ingredients may degrade or vary in concentration.
The staff also said there are few rigorous studies testing peptide safety and effectiveness. Advisory committee members, including some described by MarketWatch as pro-peptide, are not required to follow the staff recommendation.
Alec Ginsberg, who owns C.O. Bigelow Apothecaries in New York, told MarketWatch he does not sell peptides because he is not comfortable with the risk. “I would never wade into that because I won’t sell anything that I think could lead to harm, and we don’t know enough about them,” he said.
The peptides on the table
BPC-157: Used by peptide enthusiasts for issues including interstitial cystitis, knee pain and ulcerative colitis. A 2005 randomized, double-blind, placebo-controlled study in 46 ulcerative colitis patients reported improvements, according to an abstract, but FDA staff said the study lacked enough information to show safety and effectiveness.
KPV: Made from lysine, proline and valine, and used mostly for wound healing, skin health and inflammatory conditions.
TB-500: Used for wound healing and marketed for other conditions including hair loss, blood clots and dry-eye disorder, according to the FDA. It was synthesized from thymosin β4 in 2003 and has been used with horses and greyhounds for racing performance.
MOTS-C: A 16-amino-acid peptide used by some people for weight loss and weight-related concerns such as insulin resistance, osteoporosis and metabolism. It was discovered 11 years ago.
Emideltide: Also known as delta-sleep-inducing peptide, it has been promoted for insomnia, narcolepsy and opioid withdrawal. FDA staff described older clinical results from the 1980s and 1990s as inconclusive and preliminary.
Epitalon: Promoted for insomnia and first synthesized and tested in Russia in the late 1980s. The FDA once granted it orphan-drug designation, later withdrawn or revoked, for possible development in retinitis pigmentosa.
Semax: The only peptide in the group formally approved in another country, according to MarketWatch. It is cleared in Russia for stroke or optic-nerve conditions and is dispensed as nasal drops.
The advisers’ votes will not settle every fight over peptides, but they will give the FDA a public recommendation as it decides whether these products stay in the shadows or move into legal compounding channels.
This story draws on original reporting from MarketWatch.